Compared to the conventional treat-until-progression paradigm, our previous study in metastatic castration resistant prostate cancer (NCT02415621) showed that an on-and-off abiraterone therapy adapted to an individual’s PSA response dynamics provided better cancer control with less drug usage. This evidence concerns the gene KLK3 and cancer.